Is the price fair?
What QGEN's price assumes
Qiagen N.V. trades at 22.3× earnings against 35.3× for the median Diagnostics & Research name, cheaper than its own group.
22.3
Trailing P/E · Diagnostics & Research median 35.3 · cheaper than the typical name in its group
- Price / sales
- 1.20
Price / sales · as of 2025-FY
- Free cash flow yield
- 5.9%
Free cash flow yield · Diagnostics & Research median 4.2%
- Growth the price implies
- +3.4%
Growth the price implies · The price pays for +3.4% free cash flow growth a year for a decade; the business has delivered −8.2% a year over the last three.
Details›
- Price / book2025-FY
- 2.61
- EV / EBIT2025-FY
- 7.08
- EV / sales2025-FY
- 1.30
- Healthcare median P/E362 names
- 31.5
- Diagnostics & Research median P/E29 names
- 35.3
- Free cash flow, trailing twelve months
- $453M
- Market capitalisation
- $7.62B
- 3-year revenue growth
- −0.81%
- 3-year free cash flow growth
- −8.2%
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
Diagnostics & Research
Ranks #13 of 29 by Smart Score